Markets:

Overview

News

Currencies

International

Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

57.65 -0.34 (-0.59%)

Streaming Delayed Price Updated: 11:50 AM EDT, Apr 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

35 36 Next >

Better Buy: Beam Therapeutics or Intellia Therapeutics? ↗

February 22, 2023

The two clinical-stage gene-editing companies have good long-term prospects.

Via The Motley Fool

2 Bruised Growth Stocks to Buy While They're Cheap ↗

February 21, 2023

Both are on the verge of fast growth, and they haven't had any major setbacks yet.

Via The Motley Fool

SMID Cap Life Science Update: Are You An Investor Or Trader? ↗

February 20, 2023

Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.

Via Talk Markets

2 Marvelous Growth Stocks to Buy Today and Hold for 5 Years or Longer ↗

February 18, 2023

These two companies are on track to flourish through the end of the decade.

Via The Motley Fool

Beat the Dow Jones With CRISPR Therapeutics Stock ↗

February 17, 2023

If approved, CRISPR's first product may deliver blockbuster sales.

Via The Motley Fool

These 2 Biotech Stocks Could Soar in the Next Bull Market ↗

February 17, 2023

They're both at the cutting edge of gene-editing technology.

Via The Motley Fool

Top CRISPR Stocks ↗

February 11, 2023

CRISPR is a narrow niche of the biotechnology industry, but it could become the fastest growing and most significant of all the biotech businesses.

Via Talk Markets

Could CRISPR Therapeutics Stock Help You Become a Millionaire? ↗

February 10, 2023

The gene-editing business has loads of potential, but is it enough to make you rich?

Via The Motley Fool

Ready to Buy the Dip? Consider This Gene Editing Stock ↗

February 06, 2023

CRISPR Therapeutics shares had a rough 2022, but the stock might soon surge back.

Via The Motley Fool

3 Prime Healthcare Takeover Targets ↗

February 14, 2023

These three companies are attractive targets for their potential.

Via The Motley Fool

The Best Stocks To Invest $5,000 in Right Now ↗

February 12, 2023

The time is right for each of these great stocks.

Via The Motley Fool

These Cheap Growth Stocks Could Supercharge Your Portfolio ↗

February 12, 2023

All of these players are cheap today considering their growth potential.

Via The Motley Fool

Is Vertex Pharmaceuticals Stock a Buy Right Now? ↗

February 10, 2023

The drugmaker outperformed the broad market by a mile in 2022, but could there be further gains?

Via The Motley Fool

2 Biotech Stocks That Could Make You Richer ↗

February 09, 2023

Patience will pay off with these two stocks.

Via The Motley Fool

Better Bull Market Buy: CRISPR Therapeutics or Vertex Pharmaceuticals? ↗

February 09, 2023

Both stocks should be winners if gene-editing therapy exa-cel wins regulatory approvals.

Via The Motley Fool

Wall Street Expects This Stock to Jump 70% This Year. Here's Why It Could Happen. ↗

February 09, 2023

CRISPR shares are ripe for a rebound after dropping 46% last year.

Via The Motley Fool

1 Beaten-Down Stock That Has a Lot to Prove in 2023 ↗

February 08, 2023

This biotech looks like a high-risk, high-reward play.

Via The Motley Fool

3 Top Stocks to Buy If There Is a Market Pullback ↗

February 07, 2023

All three of these stocks performed well as the market fell in 2022.

Via The Motley Fool

3 Cathie Wood Stocks Wall Street Thinks Can Soar 60% to 129% ↗

February 06, 2023

Cathie Wood is bullish about these stocks. And so are Wall Street analysts.

Via The Motley Fool

When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader? ↗

February 05, 2023

A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?

Via Talk Markets

3 No-Brainer Growth Stocks to Buy in 2023 ↗

February 03, 2023

These stocks all fell by double digits last year.

Via The Motley Fool

Why Editas Medicine's Shares Jumped This Week ↗

February 03, 2023

The gene-editing biotech's shares have had a strong two-week run.

Via The Motley Fool

Is Editas Medicine Stock a Buy Now? ↗

February 03, 2023

Layoffs and a thin clinical-stage pipeline aren't very encouraging.

Via The Motley Fool

3 CRISPR Stocks to Buy Now Or You’ll Be Kicking Yourself Later ↗

February 02, 2023

CRISPR stocks are heating back up after a difficult 2022. These three names should be at the top of your watchlist.

Via InvestorPlace

Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now? ↗

February 02, 2023

Michael Burry thinks investors should sell stocks right now. Jim Cramer thinks they should buy more. Which expert is right in this case?

Via InvestorPlace

Analyst Initiates Coverage On This Peer Lagging Gene-Editing Stock ↗

February 01, 2023

Via Benzinga

Jim Cramer Says This Is 'One Of Those Crazy Science Stocks That In This Market Will Work Perfectly' ↗

February 01, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he really likes Qualtrics International Inc (NASDAQ: XM) as a

Via Benzinga

3 Things About CRISPR Therapeutics That Smart Investors Know ↗

January 31, 2023

The gene-therapy specialist's near-term outlook is quite bullish.

Via The Motley Fool

7 CRISPR Stocks With the Best Long-Term Potential ↗

January 30, 2023

CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve.

Via InvestorPlace

3 Healthcare Stocks to Buy and Hold for the Next 10 Years ↗

January 27, 2023

These companies have the therapies to boost revenue for a decade.

Via The Motley Fool

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

35 36 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.